Natera (NTRA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business performance and financial highlights

• Achieved record Q4 with 793,000 tests processed, a 26% year-over-year increase, and revenue up 52% to $472 million.

• Generated $46 million in Q4 cash flow after a $20 million technology investment, with free cash flow reaching $65 million before investment, reflecting improved operating leverage and stable expenses.

• Gross margins improved significantly, with Signatera becoming margin accretive and driving overall corporate margin expansion.

• ASPs increased due to improved Medicare Advantage reimbursement and updated ADLT rates, with further ASP growth expected in 2025.

• Strong financial position enables continued investment in R&D and infrastructure without impacting cash burn.

Product innovation and portfolio expansion

• Expanded MRD portfolio with Signatera exome, genome, and tumor-naive tests, and launched a tissue-naive MRD test with commercial launch planned for later in the year.

• Early cancer detection (ECD) test demonstrated 91.4% sensitivity and 91% specificity in screen-detected CRC cases, with further advanced adenoma data expected in 2025.

• New women's health products, including Rhesus D and 22q tests, are gaining traction and present significant ASP and revenue opportunities.

• Ongoing investment in innovation and clinical data generation remains a strategic priority.

• Advancing multiplex PCR (mPCR) technology for MRD detection and introducing tissue-free MRD assays, with a clinical launch for CRC planned in mid-2025.

Clinical evidence and market leadership

• Over 140 peer-reviewed oncology publications and multiple randomized trials support clinical utility, especially for Signatera.

• GALAXY, CALGB (Alliance)/SWOG 80702, and IMvigor011 studies are expected to further validate clinical impact and drive adoption, with key results to be presented at ASCO GI in January 2025.

• Broad Medicare coverage and unique ADLT status allow premium pricing and strong market access.

• Over 40% of U.S. oncologists are ordering Signatera, with continued growth in physician adoption anticipated.

• Extensive operational infrastructure enables rapid, scalable delivery and superior customer experience.